Kyntra Bio, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kyntra Bio, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $65 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $13 tied up three years earlier. More money tied up than 97% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-162.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 87% of Healthcare companies in United States.
Cash Locked Ratio
$65For every $100 of sales, $65 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $13 tied up three years earlier.
More money tied up than 97% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 95%
Sales fell 95% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-95% / -80%In 3 years sales changed by -95% while total assets changed by -80%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Kyntra Bio, Inc. made a loss over the last year. Kyntra Bio, Inc. owes $1.08 for every $1 it owns. Kyntra Bio, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKyntra Bio, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.62Kyntra Bio, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$19 MThe total market value of all of Kyntra Bio, Inc.'s shares at today's price (share price × number of shares), smaller than 82% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeKyntra Bio, Inc.'s net worth is negative ($30 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.08×Kyntra Bio, Inc. owes $1.08 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Dividend yield
NoneKyntra Bio, Inc. does not currently pay a dividend.
Revenue growth
-78%Revenue fell 78% in the year to Dec 2025, and shrank 64% a year on average over 3 years.
Profit growth
Back to profitKyntra Bio, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
2848.6%Kyntra Bio, Inc. keeps $2849 of every $100 of revenue as net profit.
Cash quality
-0.0×Cash from Kyntra Bio, Inc.'s business was -0.0× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
Not coveredKyntra Bio, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Questions
How much does Kyntra Bio, Inc. owe compared with what it owns?
Kyntra Bio, Inc. owes $1.08 for every $1 it owns, so it owes more than it owns, higher than 89% of Healthcare companies in United States.
Does Kyntra Bio, Inc. pay a dividend?
No. Kyntra Bio, Inc. does not currently pay a dividend.
Is Kyntra Bio, Inc.'s revenue growing?
Revenue fell 78% in the year to Dec 2025, and shrank 64% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.